Oncolys BioPharma Inc. 4588.T Stock
Oncolys BioPharma Inc. Price Chart
Oncolys BioPharma Inc. 4588.T Financial and Trading Overview
Oncolys BioPharma Inc. stock price | 706 JPY |
Previous Close | 640 JPY |
Open | 638 JPY |
Bid | 648 JPY x 0 |
Ask | 651 JPY x 0 |
Day's Range | 638 - 655 JPY |
52 Week Range | 468 - 880 JPY |
Volume | 55.4K JPY |
Avg. Volume | 141.26K JPY |
Market Cap | 11.28B JPY |
Beta (5Y Monthly) | 0.666283 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -108.92 JPY |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
4588.T Valuation Measures
Enterprise Value | 10.36B JPY |
Trailing P/E | N/A |
Forward P/E | -8.68 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 13.785437 |
Price/Book (mrq) | 6.142263 |
Enterprise Value/Revenue | 12.669 |
Enterprise Value/EBITDA | -8.934 |
Trading Information
Oncolys BioPharma Inc. Stock Price History
Beta (5Y Monthly) | 0.666283 |
52-Week Change | 25.98% |
S&P500 52-Week Change | 20.43% |
52 Week High | 880 JPY |
52 Week Low | 468 JPY |
50-Day Moving Average | 625.16 JPY |
200-Day Moving Average | 571.48 JPY |
4588.T Share Statistics
Avg. Volume (3 month) | 141.26K JPY |
Avg. Daily Volume (10-Days) | 210.1K JPY |
Shares Outstanding | 17.32M |
Float | 14.7M |
Short Ratio | N/A |
% Held by Insiders | 15.46% |
% Held by Institutions | 2.92% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -139.80% |
Operating Margin (ttm) | -141.75% |
Gross Margin | 26.10% |
EBITDA Margin | -141.81% |
Management Effectiveness
Return on Assets (ttm) | -23.61% |
Return on Equity (ttm) | -47.50% |
Income Statement
Revenue (ttm) | 818.06M JPY |
Revenue Per Share (ttm) | 47.22 JPY |
Quarterly Revenue Growth (yoy) | -81.89% |
Gross Profit (ttm) | 338.49M JPY |
EBITDA | -1160088960 JPY |
Net Income Avi to Common (ttm) | -1143668992 JPY |
Diluted EPS (ttm) | -64.85 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 1.41B JPY |
Total Cash Per Share (mrq) | 81.34 JPY |
Total Debt (mrq) | 359.44M JPY |
Total Debt/Equity (mrq) | 19.58 JPY |
Current Ratio (mrq) | 7.54 |
Book Value Per Share (mrq) | 105.987 |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Profile of Oncolys BioPharma Inc.
Country | Japan |
State | N/A |
City | Tokyo |
Address | Toranomon Towers Office |
ZIP | 105-0001 |
Phone | 81 3 5472 1578 |
Website | https://www.oncolys.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 37 |
Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company's product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use. In addition, it develops TelomeScan (OBP-401 and OBP-1101), a cancer detection drug, for detecting living circulating tumor cells in blood from cancer patients. Further, the company provides diagnostic drugs and inspection services. Oncolys BioPharma Inc. has various licensing agreements with Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Oncolys BioPharma Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.
Q&A For Oncolys BioPharma Inc. Stock
What is a current 4588.T stock price?
Oncolys BioPharma Inc. 4588.T stock price today per share is 706 JPY.
How to purchase Oncolys BioPharma Inc. stock?
You can buy 4588.T shares on the Tokyo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Oncolys BioPharma Inc.?
The stock symbol or ticker of Oncolys BioPharma Inc. is 4588.T.
Which industry does the Oncolys BioPharma Inc. company belong to?
The Oncolys BioPharma Inc. industry is Biotechnology.
How many shares does Oncolys BioPharma Inc. have in circulation?
The max supply of Oncolys BioPharma Inc. shares is 20.19M.
What is Oncolys BioPharma Inc. Price to Earnings Ratio (PE Ratio)?
Oncolys BioPharma Inc. PE Ratio is now.
What was Oncolys BioPharma Inc. earnings per share over the trailing 12 months (TTM)?
Oncolys BioPharma Inc. EPS is -108.92 JPY over the trailing 12 months.
Which sector does the Oncolys BioPharma Inc. company belong to?
The Oncolys BioPharma Inc. sector is Healthcare.